Wave Life Sciences says GSK selected siRNA program for further development

WVE•2026-09-30

Wave Life Sciences said GSK selected an siRNA program to transition to GSK for further development; Wave will receive a $12 million milestone payment and is eligible for up to $375 million in milestones per program, plus tiered royalties.

1. Program transition

Wave Life Sciences said GSK selected an siRNA program to transition to GSK for further development. Wave will receive a $12 million milestone payment for candidate selection and is eligible for up to $375 million in milestones per program, plus tiered royalties.

Wave Life Sciences says GSK selected siRNA program for further development

1. Program transition

Related News

Cytokinetics launches Aspen-HCM real-world study evaluating Myqorzo in symptomatic obstructive hypertrophic cardiomyopathy

Carvana schedules third-quarter 2026 results conference call

DFI unit to take over Maxim's stake in Starbucks Asia business, receiving $340 million

Verrica says pooled Phase 3 analysis shows YCANTH clears molluscum about 4x faster than vehicle

CarMax Inc: Truist Securities raises target price to $60 from $50